Samsung Biologics Co.,Ltd. (KRX:207940)

Market Cap	73.59T
Revenue (ttm)	4.90T
Net Income (ttm)	1.28T
Shares Out	71.17M
EPS (ttm)	17,977.18
PE Ratio	57.52
Forward PE	47.28
Dividend	n/a
Ex-Dividend Date	n/a

Volume	36,858
Average Volume	97,677
Open	1,057,000
Previous Close	1,067,000
Day's Range	1,040,000 - 1,070,000
52-Week Range	853,000 - 1,209,000
Beta	0.24
RSI	46.55
Earnings Date	Jul 22, 2025

About United States Steel

Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates through Contract Development and Manufacturing Organization (CDMO), and Biopharmaceutical Development and Commercialization segments. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, fini...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 4,770
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 207940

Financial Performance

In 2024, Samsung Biologics's revenue was 4.55 trillion, an increase of 23.08% compared to the previous year's 3.69 trillion. Earnings were 1.08 trillion, an increase of 26.31%.